Alder BioPharma: Clazakizumab Meets Primary Endpoint In Follow-on Phase 2b Trial

(RTTNews) - Alder BioPharmaceuticals, Inc. (ALDR) announced that clazakizumab, previously known as ALD518, met its primary endpoint in a follow-on Phase 2b, dose-ranging clinical trial in adults with moderate to severe rheumatoid arthritis who have experienced an inadequate response to TNF inhibitors.

The follow-on Phase 2b, dose-ranging trial was designed to determine safety and efficacy of clazakizumab in 140 patients with moderate to severe rheumatoid arthritis who were anti-TNF inadequate responders. Clazakizumab was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data, the company said.

Randall Schatzman, CEO of Alder, said, "These positive safety and efficacy findings in patients with rheumatoid arthritis provide additional support for the promise of clazakizumab as we seek a new partner to continue developing this monoclonal antibody for the treatment of autoimmune and inflammatory diseases."